
Reconstitution

Growth & Sleep · 10mg
CAS 106946-42-1
Tesamorelin, also written tesamorelin acetate, is a stabilised growth-hormone-releasing-hormone (GHRH) analogue studied for the GH/IGF-1 axis, visceral-adiposity, and metabolic pathway research. It is a synthetic analogue of the natural GHRH sequence, modified for stability, and is studied for how sustained GHRH-analogue signalling influences the growth-hormone axis in preclinical models. The 10mg vial is the standard reference format.In preclinical and in-vitro research, tesamorelin is investigated for GHRH-receptor engagement and the downstream GH/IGF-1 signalling associated with it, with particular research interest in visceral-adiposity and metabolic models. Its stabilised GHRH structure is the defining research characteristic that distinguishes it from the native hormone.Tesamorelin sits in the same GHRH-analogue family as CJC-1295; researchers comparing GH-axis approaches often study them together, and our CJC-1295 + Ipamorelin blend pairs a GHRH analogue with a secretagogue for combination work. Our Art of Pairing library guide covers the rationale. The single-compound 10mg vial here is the clean reference for tesamorelin on its own.Every 10mg vial ships lyophilised with an independently verified batch certificate at a guaranteed floor of ≥98% purity, verifiable on the batch verification page using the batch number on the label. Reconstitute with bacteriostatic water: add it slowly down the inside wall of the vial, swirl gently, and never shake. Store the unopened vial at 2 to 8°C; refrigerate once reconstituted and do not refreeze. CAS reference 106946-42-1.Buying tesamorelin in Australia is domestic: free Australia Post Express shipping to every state and territory, no minimum spend, dispatch from within Australia, and tracking on every parcel. Checkout accepts card, PayPal, or PayID, each vial is sealed under argon, and a 24-hour reservation holds your stock from order. Supplied strictly as a research material for lawful laboratory and in-vitro use, not for human or veterinary consumption.
Tesamorelin carries 127 indexed publications, 23 registered trials, 9,291 monthly readers on Wikipedia. Research activity sits at 18 papers in the past twelve months against 4 the year before.
Exact-name searches from people comparing metabolic and growth-axis peptides.
127 papers, 18 this year · 23 trials · 9,291 readers (-4%) · S tier
Prepared with care, sealed under argon, and stored at 2–8°C until dispatch. Reconstitute with Bacteriostatic Water before use. Full preparation and storage guidance included with your order.
Independent third-party research on reptides.co — not affiliated with Polaris Research. Research reference only, not medical advice.
Tesamorelin 10mg arrives sealed and research-ready, with a written preparation and storage card in every order. Prepare and store it as set out below, and use the reconstitution calculator to work out your concentration and draw volume before you begin.
Your Tesamorelin 10mg vial arrives securely packaged. Refrigerate it sealed at 2–8°C until you are ready to prepare.
Add Bacteriostatic Water slowly against the vial wall, then swirl gently. Never shake.
Once prepared, aliquot and freeze at −20°C. Avoid repeated freeze–thaw cycles.
“Well packed, sealed, and tracked door to door. Support answered my question same day.”
“Fast express dispatch and a flawless vial. Clear labelling and SKU made it easy to reference.”
“Quality was great and packaging secure. Only minor gripe was the delivery window slipping by a day.”
Educational and product-logistics information only. Nothing here is medical advice or a therapeutic claim.
A simple decision framework, start with the goal, let the goal narrow the family, and let the family narrow the compound.
Read →Sleep, nourishment, and movement, the quiet groundwork that lets everything else do its work.
Read →The single most important document in peptide research, what a COA is, what to look for, and why we ship one with every vial.
Read →Also Searched As·Tesamorelin is also searched as Tesamorelin acetate, Egrifta, Tesamorelin peptide, GHRH analogue.
Tesamorelin appears in 127 indexed publications going back to 2003, including 18 in the past twelve months. 23 registered trials appear on ClinicalTrials.gov.
Publications per year. The final bar is the current year, still in progress.
| 2015 | 5 |
|---|---|
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 0 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 17 |